©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2018; 10(9): 543-548
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.543
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.543
Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?
Heidar Sharafi, Seyed Moayed Alavian, Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran 1435915371, Iran
Heidar Sharafi, Seyed Moayed Alavian, Middle East Liver Diseases Center, Tehran 1415513651, Iran
Author contributions: Sharafi H and Alavian SM contributed to the development of the idea and drafting of the paper; both authors read and approved the final version of the manuscript.
Conflict-of-interest statement: Both authors declare no potential conflict of interest.
Correspondence to: Heidar Sharafi, BSc, MA, MPhil, MSc, PhD, Research Scientist, Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran 1415513651, Iran. h.sharafi@meldcenter.com
Telephone: +98-21-88945186 Fax: +98-21-88945188
Received: June 7, 2018
Peer-review started: June 7, 2018
First decision: July 11, 2018
Revised: July 19, 2018
Accepted: August 4, 2018
Article in press: August 4, 2018
Published online: September 27, 2018
Processing time: 112 Days and 19.4 Hours
Peer-review started: June 7, 2018
First decision: July 11, 2018
Revised: July 19, 2018
Accepted: August 4, 2018
Article in press: August 4, 2018
Published online: September 27, 2018
Processing time: 112 Days and 19.4 Hours
Core Tip
Core tip: Hepatitis C virus resistance to NS5A inhibitors is one of the main problems of treatment with NS5A inhibitors. While the treatment of NS5A inhibitor-naïve patients is feasible and efficient, retreatment of NS5A inhibitor-experienced patients is challenging. In the context of failure following treatment with NS5A inhibitor-containing regimens, NS5A resistance-associated substitution testing can help in clinical decision-making, while the usefulness of baseline NS5A resistance-associated substitution testing in NS5A inhibitor-naïve patients is in question.